Cipla surges on receiving USFDA nod to market Lanreotide injection in US
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Cipla is currently trading at Rs. 875.25, up by 16.80 points or 1.95% from its previous closing of Rs. 859.85 on the BSE.
The scrip opened at Rs. 865.95 and has touched a high and low of Rs. 881.05 and Rs. 862.65 respectively. So far 0.21 lakh shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1,005.00 on 29-Sep-2021 and a 52 week low of Rs. 738.25 on 19-Mar-2021.
Last one week high and low of the scrip stood at Rs. 907.85 and Rs. 907.85 respectively. The current market cap of the company is Rs. 70,726.97 crore.
The promoters holding in the company stood at 36.12%, while Institutions and Non-Institutions held 45.83% and 18.05% respectively.
Cipla has received approval from the US Food and Drug Administration (USFDA) to market the Lanreotide injection in the American market. The Lanreotide injection is used for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors.
This approval is a significant step for its US business and is in line with its aspiration to continue growth in its complex product pipeline and address unmet patient needs.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
